Core Viewpoint - The article highlights the recognition of Fangzhou Jianke for its innovative contributions in the "AI + chronic disease management" sector, emphasizing its role as a benchmark in the healthcare industry and its commitment to social responsibility [1][4]. Group 1: Awards and Recognition - Fangzhou Jianke received the "Social Responsibility Golden Bull Award" at the 2025 Xiamen Industrial Development Conference, acknowledging its forward-looking exploration and breakthrough technological achievements in the healthcare sector [1]. - The Golden Bull Award is a prestigious evaluation activity by China Securities Journal, emphasizing transparency and professionalism in recognizing high-quality development among Hong Kong-listed companies [3]. Group 2: Technological Innovation and Strategy - The company has integrated AI technology into its operations, creating a new ecosystem called AI + H2H (Hospital To Home), which enhances the efficiency and accuracy of chronic disease management [4]. - Fangzhou Jianke's AI technology has been recognized as a key driver for high-quality development in the healthcare sector, aligning with national policies promoting AI in medical applications [4]. Group 3: Social Impact and Community Engagement - The company has established partnerships, such as the AI + Viral Hepatitis Prevention and Control Training Base with the Guangdong Provincial Liver Disease Research Institute, to empower healthcare for liver disease patients [5]. - Fangzhou Jianke actively participates in rural revitalization initiatives, leveraging AI to improve healthcare accessibility in remote areas, thereby reducing time and medical costs for underserved populations [5]. Group 4: Future Directions - The company aims to continue leading in the digital transformation of chronic disease management while promoting high-quality development in the healthcare industry through technological empowerment [6].
“AI + 慢病管理”创新突围 方舟健客获颁“社会责任金牛奖”